Exposure to PFAS has been linked to deadly cancers, impacts to the liver and heart, and immune and developmental damage to infants and children.
These associations above largely come from human epidemiological research (statistical patterns in population studies of PFAS exposure). For some compounds, the evidence shows causation, not just correlation: an agency of the World Health Organization has classified PFOA as carcinogenic to humans, and PFOS as possibly carcinogenic. However, whether reducing PFAS blood levels lowers the risk of any specific condition has not been established in clinical trials and remains under active study. What research has addressed is where PFAS goes in the body, why they persist, and how they can be cleared.
Your body is a master recycler, pulling nutrients from the gut into the blood so nothing essential goes to waste. But forever chemicals and other pollutants hijack these recycling systems. As a result, PFAS stay in your body for years or even decades, causing escalating damage with each pass through the system.
Over the past few years, researchers have identified existing medications that interrupt this PFAS recirculation pathway. In the studies referenced below, these medications appear to bind PFAS in the gastrointestinal tract, so that PFAS pass out of the body in stool rather than being reabsorbed into the bloodstream.
Importantly, these medicines are well-studied and well-tolerated. Unlike many other drugs, these only act in the digestive tract and are not absorbed into the bloodstream, so systemic side effects are negligible.
Faster PFAS clearance with medication
vs. natural elimination1
1Based on within-study comparisons of PFAS reduction during treatment vs. untreated control periods in the same participants (Andersson et al. 2025). In this cross-over clinical trial, conducted in adults from a PFAS-contaminated community, serum PFAS declined ~2–20x faster during treatment than during untreated control periods. Effect size varies by PFAS compound. Individual results depend on baseline levels, ongoing exposure, and adherence.
Multiple studies have reported that certain existing medications can dramatically accelerate the clearance of PFAS from the body.
When researchers analyzed 50,000+ health records, they found something surprising: people taking certain common medications had significantly lower PFAS levels than expected. These medications were associated with lower PFAS levels even though that wasn't why they were taking them.
Read the study →The first controlled trial tested these medications' ability to reduce five different PFAS compounds. Treatment reduced all five types of PFAS, with levels of one particularly dangerous compound (PFOS) dropping 60% more than controls in just 12 weeks.
Read the study →Firefighters face some of the highest PFAS exposures of any group. This study showed medication effects even in high-exposure cases: firefighters’ PFOS half-life dropped from over 7 years to just 1.2 years, substantially reducing body burden.
Read the study →An independent Swedish cohort reported similar results: these medications reduced PFOS levels by nearly 40% in one quarter. The control group during the same period? Just 2%. A meaningful acceleration over natural clearance.
Read the study →